Glipizide is a second-generation sulfonylurea that lowers blood sugar by triggering the pancreas to release more insulin. It cuts A1C by about 1 to 1.5 percent, costs $4 to $15 a month as a generic, and carries two main downsides: hypoglycemia and weight gain of 2 to 5 kg. Modern guidelines favor metformin, GLP-1 agonists, and SGLT2 inhibitors over sulfonylureas when those are affordable — but glipizide remains a useful tool in cost-constrained care and as add-on therapy.
How Glipizide Works
Glipizide binds the SUR1 (sulfonylurea receptor 1) subunit on the surface of pancreatic beta cells. This closes ATP-sensitive potassium channels, depolarizing the cell membrane and triggering calcium influx — which in turn pushes the cell to release stored insulin granules.
The key feature: glipizide stimulates insulin release whether or not blood glucose is high. That glucose-independent stimulation is why hypoglycemia is the dominant side effect of the entire sulfonylurea class.
- Drug class: second-generation sulfonylurea
- Brand names: Glucotrol (immediate-release), Glucotrol XL (extended-release)
- Generic status: yes, widely available
- Onset of glucose effect: 30 minutes
- Peak effect (IR): 1 to 3 hours
- Duration (IR): 10 to 16 hours
- Duration (XL): around 24 hours
- Excretion: hepatic metabolism with renal clearance of inactive metabolites
Approved Uses
Glipizide is FDA-approved as an adjunct to diet and exercise in adults with type 2 diabetes. It is not used for type 1 diabetes (no functional beta cells to stimulate), diabetic ketoacidosis, or prediabetes as monotherapy. Some clinicians use it off-label as bridging therapy in steroid-induced hyperglycemia or in cost-constrained patients failing on metformin alone.
Typical Dosing
| Formulation | Starting Dose | Maximum Dose | Timing |
|---|---|---|---|
| Glipizide IR (Glucotrol) | 5 mg once daily | 40 mg/day (divided) | 30 minutes before breakfast; split if >15 mg/day |
| Glipizide XL (Glucotrol XL) | 5 mg once daily | 20 mg/day | With breakfast, swallow whole |
| Older adults | 2.5 mg once daily | Titrate slowly | Before breakfast |
Doses are titrated upward by 2.5 to 5 mg every 1 to 2 weeks based on fasting glucose. Above 15 mg of IR glipizide, doses are typically split before breakfast and dinner. The XL form does not need splitting.
What to Expect on A1C
- A1C reduction: roughly 1.0 to 1.5 percent — similar in magnitude to metformin
- Fasting glucose: 30 to 60 mg/dL reduction is typical
- Peak effect on A1C: by 8 to 12 weeks of stable dosing
- Secondary failure: a known issue — the ADOPT trial showed sulfonylureas had higher rates of failing to control glucose at 5 years compared with metformin and rosiglitazone, likely from progressive beta-cell decline
Common Side Effects
- Hypoglycemia — sweating, shakiness, fast heartbeat, hunger, confusion, headache. Less severe and shorter-lasting than with glyburide in most patients but still the dominant risk.
- Weight gain — typically 2 to 5 kg over the first year because insulin promotes fat storage.
- Mild GI upset — nausea, fullness, diarrhea
- Dizziness or drowsiness, particularly when starting
- Headache
Serious but Less Common Side Effects
- Severe or prolonged hypoglycemia requiring emergency treatment
- Sulfa-class allergic skin reactions (rare; true cross-reactivity with sulfonamide antibiotics is overstated)
- Photosensitivity rash
- Hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Cholestatic jaundice and hepatitis (very rare)
- Hyponatremia or SIADH (uncommon; more associated with older first-generation sulfonylureas)
Who Should Be Cautious or Avoid Glipizide
- Adults over 75, particularly those who live alone or have cognitive impairment
- Significant kidney disease (eGFR <30 mL/min) — risk of prolonged hypoglycemia
- Liver disease — altered metabolism
- Frequent meal-skippers, irregular shift workers, or people on calorie-restricted diets
- Heavy or binge alcohol drinkers
- Prior severe hypoglycemic episode
- Pregnancy and breastfeeding — insulin is preferred
- Known sulfonylurea allergy
Drug Interactions
- Beta-blockers — can mask hypoglycemia warning signs (sweating still occurs but tremor and tachycardia are blunted)
- CYP2C9 inhibitors (fluconazole, amiodarone, sulfa antibiotics) — increase glipizide levels
- Warfarin — protein-binding interaction can shift either drug
- NSAIDs and salicylates — augment hypoglycemic effect
- Corticosteroids and thiazide diuretics — oppose blood-sugar-lowering effect
- Alcohol — increases hypoglycemia risk and rarely causes disulfiram-like reactions
Glipizide Compared to Other Diabetes Drugs
| Drug | A1C Drop | Weight | Hypoglycemia | Cost/Month |
|---|---|---|---|---|
| Metformin | 1.0 to 1.5% | Neutral or modest loss | None alone | ~$4 |
| Glipizide | 1.0 to 1.5% | +2 to 5 kg | Common | $4 to $15 |
| Glyburide | 1.0 to 1.5% | +3 to 5 kg | More common, more severe | $4 to $15 |
| Glimepiride | 1.0 to 1.5% | +2 to 4 kg | Common but less than glyburide | $4 to $15 |
| GLP-1 agonists | 1.0 to 2.0% | −4 to 15 kg | Rare alone | $500 to $1,300 |
| SGLT2 inhibitors | 0.5 to 1.0% | −2 to 4 kg | Rare alone | $500 to $700 |
Where Glipizide Fits in 2024 Guidelines
The American Diabetes Association Standards of Care 2024 places sulfonylureas later in the algorithm than they once were. Modern first-line therapy for type 2 diabetes is metformin plus, where indicated, a GLP-1 receptor agonist or SGLT2 inhibitor. Sulfonylureas are usually reserved for:
- Cost-constrained patients
- Add-on when A1C remains above target on metformin and newer agents are unaffordable
- Patients without significant cardiovascular, kidney, or heart failure considerations that would favor the newer classes
Tips for Living with Glipizide
- Take exactly 30 minutes before breakfast (IR) so peak insulin matches the meal
- Never skip a meal after taking a dose
- Carry fast-acting glucose (glucose tabs, juice box, regular soda) at all times
- Teach a family member the rule of 15 — 15 g carbs, recheck in 15 minutes
- Test glucose more often when starting, dose-changing, or sick
- Wear medical ID
- Tell every prescriber and pharmacist you are on a sulfonylurea before any new prescription
Related Reading
See our companion guides on glipizide vs metformin, the broader sulfonylureas list, and class-level sulfonylureas side effects. Background on A1C levels may also help in setting glipizide treatment goals.
The Bottom Line
Glipizide remains a cost-effective second- or third-line option for type 2 diabetes. It lowers A1C by 1 to 1.5 percent, costs little, and works through insulin secretion — but that mechanism also drives its two defining downsides: hypoglycemia and weight gain. Most modern guidelines favor metformin first, then GLP-1 agonists or SGLT2 inhibitors when affordable, with glipizide reserved as an add-on or in cost-limited care. People over 75, with kidney disease, heavy alcohol use, or unpredictable meals are not ideal candidates. Anyone considering glipizide should talk to their clinician about whether the savings justify the hypoglycemia risk in their specific case.
